|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/352 | (2006.01) |
| A61K 45/06 | (2013.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61K 31/164 | (2013.01) | ||
| A61K 31/57 | (2006.01) | ||
| A61K 31/473 | (2013.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61K 31/565 | (2013.01) | ||
| A61K 31/164 | (2006.01) | ||
| A61K 31/573 | (2013.01) | ||
| A61K 31/57 | (2013.01) | ||
| A61K 31/473 | (2006.01) | ||
| A61K 31/565 | (2006.01) | ||
| A61K 31/568 | (2013.01) | ||
| A61K 31/568 | (2006.01) | ||
| A61K 31/352 | (2013.01) | ||
| A61K 31/573 | (2006.01) | ||
| A61K 9/0014 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 21/02 | (2006.01) | ||
| A61P 1/10 | (2018.01) | ||
| A61P 25/16 | (2006.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 25/28 | (2006.01) | ||
| A61P 13/02 | (2018.01) | ||
| A61P 27/02 | (2006.01) | ||
| A61P 21/02 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 25/02 | (2018.01) | ||
| A61P 25/08 | (2018.01) | ||
| A61P 25/16 | (2018.01) | ||
| A61P 25/18 | (2018.01) | ||
| A61P 25/20 | (2018.01) | ||
| A61P 25/22 | (2018.01) | ||
| A61P 25/24 | (2018.01) | ||
| A61P 25/28 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 27/16 | (2018.01) |
| (11) | Number of the document | 3509585 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17849385.4 |
| Date of filing the European patent application | 2017-09-05 | |
| (97) | Date of publication of the European application | 2019-07-17 |
| (45) | Date of publication and mention of the grant of the patent | 2023-11-01 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/050055 |
| Date | 2017-09-05 |
| (87) | Number | WO 2018/048789 |
| Date | 2018-03-15 |
| (30) | Number | Date | Country code |
| 201662384458 P | 2016-09-07 | US |
| (72) |
CHANG, Wei-wei , US
SAWYER, Kenneth I. , US
|
| (73) |
Glia, LLC ,
134 Saint Botolph Street, Boston, Massachusetts 02115-4819,
US
|
| (54) | TREATMENT OF SYMPTOMS RELATED TO NEURODEGENERATIVE DISORDERS THROUGH PHARMACOLOGICAL DERMAL ACTIVATION OF CRANIAL NERVES |
| TREATMENT OF SYMPTOMS RELATED TO NEURODEGENERATIVE DISORDERS THROUGH PHARMACOLOGICAL DERMAL ACTIVATION OF CRANIAL NERVES |